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Abstract
Biotechnology is changing greatly over recent years, providing huge benefits to human society. However,
the ethics, safety, and negative externalities of biotechnology have become increasingly prominent.
Currently, biotechnology is still in the early stage of development, and full of high uncertainty.
Technological changes in this field have the characteristics of stronger subversiveness, complexity, and
social relevance. The world is facing a process of great development of biotechnology, new outbreaks of
ethical challenges, and ethical governance reforms. China should take this opportunity to promote the
high-quality development of biotechnology on the one hand, and on the other hand, adopt a multi-pronged
approach to achieve comprehensive, flexible, and sustainable governance of ethical issues by conducting
forward-looking ethical risk research and judgment, improving regulatory system, encouraging the
participation of multiple stakeholders, and taking part in global governance, etc.
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The world is experiencing the profound changes unseen in
a century, with a new round of scientific and technological
revolution and China’s transformation of its development
mode. As one of the cutting-edge and booming research
fields in the 21st century, biotechnology is changing rapidly
and has become an important engine of this scientific and
technological revolution. The development of biotechnology
will subversively change scientific research, public health,
agriculture, energy, and environmental protection, bringing
huge benefits to the human society and altering the global
scientific and technological, political, economic patterns.
Moreover, it may even affect the process of human beings.
However, as the relationship between science and technology and the society is experiencing a paradigm shift [1],
ethics, safety, and negative externalities accompanying the
development of biotechnology have become increasingly
prominent. Learning from history, we should realize that any
science and technology that promotes the progress of human
society, changes the course of the world, and triggers fundamental changes in human life requires effective governance and compliance with ethical norms. The currently great
changes in biotechnology provide China with not only a key
opportunity to boost the high-quality development of biotechnology but also a rare strategic condition to shape the
innovation ideas, advance the modernization of the national

ethical governance system and capacity, and participate in the
global governance on ethics of biotechnology.

1

Development and trend of biotechnology

The booming of biotechnology has expanded the scope of
bio-economy to many fields in recent years and will gradually lead to the development of global economy in the future [2]. In particular, the frontier fields such as stem cells,
synthetic biology, and gene editing have developed rapidly.
The research papers in the three fields have been increasing
rapidly since 2000 (Figure 1). Specifically, the number of
annually published papers focusing on stem cell research has
exceeded 20 000 by 2016 and remained stable in the following years. The number of papers concerning synthetic
biology has grown greatly since 2010. The number of papers
regarding the research and application of gene editing technology has raised sharply after the emergence of CRISPRCas9 in 2012 and is still growing rapidly.
The progress in new general technologies such as singlecell sequencing, high-resolution imaging, and gene editing
has fostered new breakthroughs in stem cell research.
Moreover, the integration of stem cell research with new
biomaterials, 3D printing and other new technologies has
given birth to new fields such as organ-on-a-chip, organoids,
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Figure 1

Number of articles related to stem cells, synthetic biology, and gene editing from 2000 to 2019

Database: Web of Science. Search time: Oct.15, 2020. Database update time: Oct.14, 2020. Search keywords: genome edit, gene edit, CRISPR, TALEN,
ZFN; Stem cell; artificial life, synthetic biology. Document type: article + review.

and chimeras. In the field of stem cells, the United States,
China, Germany, Japan, and the United Kingdom published a
large number of papers from 2010 to 2019. Specifically, the
United States published 62 159 relevant papers, which accounted for 34.76% of the global total volume, much more
than those in other countries. Since 2010, the number of
annually published papers associated with stem cells in China
has surpassed that of developed countries such as the United
Kingdom and Germany, rising to the second in the world,
with the growth rate significantly higher than that of other
countries in the following 10 years (Figure 2a). In the field of
synthetic biology, the annual growth rate of papers published
globally was above 10% from 2010 to 2019 (Figure 2b).
Specifically, the number of papers published in the United
States reached 26 138, accounting for 35.46% of the global
total volume; China ranked second in the world with 18 388
papers and a high growth rate. In 2019, China surpassed the
United States in the number of papers related to synthetic
biology, ranking first in the world (Figure 2b). In the field of
gene editing, the United States published 7 751 papers during
this 10-year period, which accounted for 47.51% of the
global total volume; China ranked second with a total of
3 732 papers (Figure 2c). In the past five years, China’s average growth rate of the papers concerning gene editing has
exceeded 50%, being similar to that in the United States.
In general, global biotechnology is booming and the frontiers are still in the early stage of development. Compared
with developed countries, China starts late in the development of biotechnology, which is thus characterized by overall
weak strength and unsound system construction. However,
with the substantial investment of the government in recent
years, China’s biotechnology has developed rapidly and
caught up with developed countries. In some cutting-edge
fields such as stem cell, regenerative medicine, and synthetic

Figure 2 Number of published articles in the top five countries in
the fields of stem cells (a), synthetic biology (b), and gene editing
(c) from 2010 to 2019
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biology, China is now in a world-class or even leading position as it does not lag behind the developed countries in the
beginning. It can be said that in some fields, China and other
technologically developed countries have stepped into the
frontier or no-man’s land.

2
Development
biotechnology

characteristics

of

Biotechnology, especially the frontiers, is making robust
progress, while the technological development path and direction, application mode, and scenarios are highly uncertain.
At the same time, biotechnology is being integrated with
other emerging fields such as big data, artificial intelligence,
and nanotechnology rather than developing solitarily, which
is thus experiencing accelerated iteration. More importantly,
compared with traditional biotechnologies, the state-of-theart biotechnologies have strong subversiveness, complexity,
and social relevance.
(1) Subversiveness. In the 21st century, the accuracy, efficiency, simplicity, and cost of biotechnological fields such
as CRISPR-Cas and synthetic biotechnology have been
greatly improved, which has promoted the civilianization and
accessibility of knowledge and technology in the fields [3].
Such development has gradually altered the situation that
biological research can only be conducted in large laboratories and enterprises and spawned a variety of small laboratories and workshop-style research fields such as garage
biology. In this way, such technologies can be extended to
other fields like medicine, pharmacy, chemical industry,
energy, and environmental protection in a very short period of
time, which may rapidly and profoundly reshape the development paths and industrial structures in these fields.
(2) Complexity. The complexity here is reflected in the
following three aspects. ① The knowledge and technology of
biotechnology are difficult for ordinary people to understand
and master. As the field is being subdivided, even biologists
have difficulty in judging subdivisions they are unfamiliar
with, let alone policy makers and the public. This feature
makes the decision logic underlying the technologies in this
field difficult to understand, predict, and evaluate. ② The
design and manufacture of biotech products are separated.
For example, synthetic biology, which studies biological
systems by engineering, is facing the separation of analysis,
system design, and manufacturing processes, i.e., the steps in
the design-build-test (DBT) cycle [4]. The aggravation of such
separation will make potential ethical issues more complicated and governance more difficult while improving the
accessibility of technology [5]. ③ Biotechnology is developing from a linear model to an open networked model. It is
experiencing the integration of multidisciplinary concepts
and knowledge, while its materials, data, and methods are
more open and shared. Biotechnology has attracted more
experts or “hobbyists” from other fields and it is no longer

just the domain of biologists, which has increased the personnel complexity in the field.
(3) Social relevance. Traditional biological research
mainly observes and explains life, so there is usually a large
gap between basic research and application. However, modern biotechnology is closely related to human life and has
been put into application since its emergence, producing huge
social influence. At present, biotechnology has been deeply
integrated into all fields of the society. Moreover, cuttingedge biotechnologies such as gene editing and synthetic
biology have the ability to change the occurrence and evolution of life including human beings at the genetic level, and
can transform or even create life. These technologies hit the
root of life, human nature, and self-identification, arousing
concerns of the public. Therefore, modern biotechnology has
stronger social relevance than traditional biotechnology.

3
Ethical issues and new challenges of
biotechnology
From the history of biotechnology in the past 40 years, we
can see that the birth and application of emerging biotechnologies, from test-tube babies to pre-implantation diagnosis
and screening, from stem cell research to cloning technology,
and from synthetic biology to gene-edited embryos, have
caused extensive and repeated social concerns and ethical
controversies. These emerging biotechnologies stem from the
huge demand for scientific and technological progress in
social development. At the same time, they impact social
culture and ethical values and promote the change in relevant
rules and the rearrangement of the system. Importantly, biotechnology is gradually becoming networked and open and
has been considered an emerging technology field spanning
multiple industries and sciences. Therefore, the ethical risks it
brings may vary widely in different domains.

3.1 Frontier ethical disputes in the development of
stem cell technology
Traditional ethical disputes in the field of stem cells
mainly focus on human embryonic stem cell research and
human cloning. Human embryonic stem cell research involves the extraction of stem cells from early embryos (5–7
days after sperm-egg binding) and the establishment of cell
lines for reuse. Therefore, the core of the ethical controversy
is the ethical status of embryos. To be specific, whether the
embryos are human and whether they can be used for research. However, because of the differences in technological
development and the diversity of cultural and social concepts,
how to define human and embryo varies, and the relevant
laws and policies also vary among different countries. The
currently adopted international rule, namely, the “14-day
rule” [6], has been adopted for almost 40 years. In addition,
regarding therapeutic cloning and reproductive cloning, the
international community has basically reached a consensus
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on prohibiting human reproductive cloning, whereas the
ethics of therapeutic cloning is still in debate [7].
The above-mentioned ethical controversies in the early
2000s seem to have come to an end. However, with the maturity and application of biotechnology platforms such as
gene editing, large-scale culture, and biomanufacturing in
recent years, stem cell-related technologies have advanced
from the molecular level to the tissue level and from basic
research to practical application. The two cutting-edge research directions, chimera and organoids, based on stem cells
have reignited the ethical controversy about what is an embryo and what is a human being, and also spawned more new
ethical challenges. For example, chimera research involves
the chimerism between human and non-human animal bodies
or embryos. Accordingly, the ethical disputes are not limited
to stem cell and embryo research, instead, they gradually
extend to the boundary between humans and animals [8], the
implications of the potential use of chimeras, and the possibility of conferring human status on animals [9]. In addition,
the research and application of chimeras induces a series of
controversies such as the risks of violating human dignity,
violating animal welfare and rights, causing the uneven allocation of medical resources, and transmitting the disease
from animals to humans [10]. This has completely gone beyond the traditional ethical debate over the status of embryos.
In the research on organoids, controversies are aroused in
the fields like the possibility of brain organoids being “conscious” [11], how to define consciousness [12], and the limitations or special censorship of specific studies [13]. In addition,
stem cell-based embryo model research also faces disputes on
consciousness and self-knowledge, and research in this field
involves the ethical risk of crossing the “14-day rule” [14].
These ethical disputes not only are rich in profound philosophical connotations but also have profound legal and social
influences, going far beyond traditional ethical disputes on
stem cells. The development and reform of stem cell technology lead to the rekindling and spreading of ethical disputes in this field.

3.2 New ethical and safety challenges for synthetic
biology
Although synthetic biology emerged in the 1960s, it has
only gradually developed in the past ten years. As an
emerging technology, synthetic biology has also raised many
ethical controversies. Specifically, synthetic biology aims to
use the ideas of engineering to modify or create biological
systems or organisms with special purposes, so the new ethical challenges it poses are special, involving both conceptual
and non-conceptual ones [15]. The conceptual new ethical
challenges mainly focus on the debate over concepts such as
life and nature, such as the critical ethical analysis of the
concepts like “life” and “non-life”, and “natural” and “artificial”. This involves issues such as whether synthetic life
challenges the traditional concept, value, and meaning of life.
The non-conceptual new ethical challenges focus on the

potential application of synthetic biology in different fields,
mainly involving biosafety, biosecurity, as well as the fairness and justice of resource allocation in the application of
this technology.
Biosafety and biosecurity are key ethical concerns arising
from the latest progress in synthetic biology. Biosafety is a
general issue concerning the risks of synthetic biology to
human health and the eco-environment, mainly covering
three issues: biological error, accidental exposure of synthetic
organisms, and accidental release of synthetic organisms to
the environment [5]. The concerns of the latter two issues are
greater. A more controversial ethical concern in synthetic
biology is biosecurity [16]. This issue involves the abuse of
biological agents, materials or technologies, like the theft,
diversion, or deliberate release of biological agents or materials to endanger human health or the eco-environment. In
particular, the biological weapons and terrorism threats have
attracted much attention. From a technical standpoint, scientists have been able to create or reanimate deadly viruses such
as poliovirus [17], 1918 Spanish influenza pandemic virus [18],
horsepox virus [19], and Ebola virus [20] in the laboratory. As a
result, people will worry about that the development of synthetic biology provides more possibilities for the upgrading
of biological weapons, and the barriers for malicious actors to
acquire and use biological weapons will be correspondingly
weakened or eliminated [21]. This may guide countries to
utilize synthetic biology to develop biological weapons, and
terrorists can use this technology to create bioterrorism. Like
computer hackers, biohackers may also try to create viruses
out of curiosity or to demonstrate their technical prowess [22],
thereby causing unprecedented harm to humans.

3.3 New ethical concerns in the application of
gene editing technology
Gene editing, especially CRISPR-Cas, is a disruptive biotechnology developed in recent years. Compared with traditional gene editing technologies such as zinc finger
nucleases (ZFNs) and transcription activator-like effector
nucleases (TALENs), CRISPR-Cas is characterized by easy
operation, low cost, and high efficiency. However, just like
the “gene-edited babies” incident at the end of 2018, the
potential application of gene editing to human body has
caused unprecedented ethical concerns. These concerns focus
primarily on alterations to the human germline genome in
three dimensions.
In the individual dimension, ethical concerns are mainly
about the safety of technology application. The current gene
editing technology has defects such as off-target effect, which
may lead to unintended editing with unknown consequences.
In human germline gene editing, the potential risk of
off-target or unintended consequences cannot be determined
at present.
In the family dimension, the widespread application of
human germline gene editing may lead to changes in the
family structure, as well as the natural emotions and perceptions
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between parents and children [23]. If some genetic diseases or
traits can be easily changed by gene editing, parents will be
more likely to perceive but more difficult to tolerate the imperfections of their children, and the parents’ instinct to unconditionally accept their children will be impacted. In
addition, the application of human germline gene editing may
alter the consistency of interests between parents and children, which poses a challenge to the protection of children
autonomy in the future.
In the society dimension, human germline gene editing
first arouses eugenic concerns. Because of the popularity of
this technology, some people will specifically breed offspring
with preferred genetic characteristics, which will increase
social prejudice and discrimination [24]. In addition, attention
should also be paid to the potential social fairness and justice
in the application of this technology. People worry that the
application of this technology will become the “patent” of the
rich, which will further solidify the existing injustice in the
society and aggravate the differentiation of social classes.
Other ethical concerns include the commercialization of
“designed babies”, human augmentation, and moral
decline [25].
In addition to the above-mentioned applications to the
human body, gene editing is increasingly applied to
non-human animals, such as the improvement of domestic
animals, the construction of laboratory animal models, the
control of invasive species/diseases, the construction of
chimeras, and the recovery of endangered and extinct species.
The research and applications of non-human animal gene
editing also raise social and ethical challenges to food safety,
biosafety, justification for creating laboratory animal models,
animal welfare and rights, and public trust in scientific research. Compared with that of human germline gene editing,
the research and application of animal gene editing may
impose greater ethical challenges, so the scientific community, policy makers, and regulators need to maintain high
attention.

4
China’s exploration in
governance of biotechnology

the

ethical

Biotechnology is developing and will develop rapidly. The
technological changes in this field will inevitably bring an
impact on social morality, values, legal rules, and even politics and economy. At the same time, the uncertainties, subversiveness, and complexity of biotechnology development
make the ethical risks in this field increasingly complex and
unpredictable. To avoid the occurrence of the ethical events
such as Black Swan and Gray Rhino, ethical governance is in
urgent need. In 2019, the 4th plenary session of the 19th
Central Committee of the Communist Party of China (CPC)
passed the Decision of the CPC Central Committee on Some
Major Issues Concerning Upholding and Improving Socialism with Chinese Characteristics and Modernizing National

Governance System and Capacity, which specified to improve the ethical governance mechanism for science and
technology. The Outline of the 14th Five-Year Plan for
Economic and Social Development (2021–2025) and
Long-Range Objectives through the Year 2035 of the People’s Republic of China also emphasized the improvement of
the ethical governance system. Compared with improving the
ethical governance mechanism, the word “system” reflects
China’s higher and comprehensive requirements for the ethical governance of science and technology.
The ethical governance of science and technology may
have two problems. Insufficient governance will lead to excessive or unknown ethical risks and weaken public confidence, while excessive governance will limit the
development of cutting-edge biotechnology. The enormous
potential benefits and uncertain ethical risks pose unique and
huge challenges to the governance in today’s society [26].
Faced with this emerging field, especially the fact that ethical
disputes vary in different fields and gradually spread with the
development of biotechnology, ethical governance should not
be handled with a fixed process or framework. According to
the nature, characteristics, development trend, and application fields of specific biotechnology, flexible governance
should be carried out. The traditional linear process from the
public and expert opinion to policy formulation is also no
longer feasible, and a parallel, predictive, forward-looking
process will be more practical. In general, China’s main
strategic orientation to strengthen the ethical governance of
biotechnology should include the following six aspects.
(1) Conducting forward-looking research and judgment on
the ethical risks of biotechnology and deepening the research
on China’s governance system and structure to improve
China’s ethical governance plan. At present, countries around
the world lack sufficient experience in ethical governance of
cutting-edge biotechnology. While strengthening the practice
of forward-looking research and judgment on the ethical risks
of biotechnology, China is committed to promoting the innovation of ethical governance strategies. It keeps pace with
the development of cutting-edge sub-fields, identifies technical characteristics, evaluates development laws and trends,
and conceives application scenarios to promote the discussion and research of ethical issues in the context of Chinese
culture and technological development. China should collect
and develop available data and information as much as possible in an environment with constantly changing knowledge,
identify the ethical risks based on the latest data, assess expected impacts, and measure knowledge gaps to seek solutions. With the National Ethics Committee for Science and
Technology at the core, China’s ethical governance should
aim to cultivate a team of talents for research and management, deepen the research on the governance system and
structure, and give full play to its strategic research and
decision-making consulting role, so as to improve the national capacities in the judgment and the decision-making
regarding ethical risks in science and technology.
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(2) Constructing the national legal system and regulatory
system to consolidate the foundation of China’s ethical governance in biotechnology. On the whole, China’s legislation
in this field is still lagging behind with unsound system. The
new ethical challenges of cutting-edge biotechnology have
overturned the traditional legal assumptions to a certain extent and affected the existing legal basis, framework, and
even some legal principles [27]. Therefore, China needs to
intensify efforts to build a legislative mechanism that adapts
to the characteristics of biotechnology development, improve
the quality of legislation, and form a rational and forwardlooking legal system [28]. In addition, China should combine
abstract legal principles, specific legal rules, and flexible
regulatory policy tools together based on the current status
and differences in biotechnology development in China and
abroad, and flexibly adjust governance according to the
evolution of ethical risks or hazards in subdivided fields [29].
The role of the National Ethics Committee for Science and
Technology should be given full play to the decision-making
and regulatory consultation of ethical governance. Through
the coordination of the committee, the existing decentralized
ethics supervision system should be modified to improve the
coordination of the actions and analysis abilities among and
within regulatory agencies [29] and overcome the uncertainties
and risks of biotechnology with limited resources.
(3) Giving full play to the supervision and management
roles of research institutions as the main body and improving
the business capabilities of ethics review committees. Ethical
issues run through the entire research and application cycle of
biotechnology. Research institutions are the best subjects for
ethical supervision of research projects, playing an increasingly prominent role [30,31]. China should strive to build an
institutional ethics supervision system that is compatible with
its own legislative supervision system and cultural tradition
and basically symmetrical with scientific and technological
development and ethical governance. At present, China
should improve the ethical review system and effectively
review the ethical issues during the design and implementation of the research projects involving biotechnology. Efforts
should be made to strengthen the review capacity building of
members in ethics committees at all levels across the country,
and improve the professional review level of the committees.
In the construction of the ethical review system, special ethics
committees or procedures can be established for specific
fields to reduce potential ethical risks and improve China’s
ability to manage ethical risks of special biotechnologies.
(4) Steadily promoting the self-discipline construction of
the scientific and technological community by proposing and
implementing the Chinese plan for the autonomy of the scientific and technological community. China must deeply
realize that the ethical governance of science and technology
cannot rely solely on “top-down” supervision, but should
involve the participation of multiple stakeholders including
scientists and enterprises through various types of autonomy
or self-discipline. It is suggested to improve the education

and training on the ethics of scientific research, help relevant
personnel improve their ethics and legal awareness and skills,
and foster correct values on life, safety, fairness, and justice,
so as to create a basic environment for responsible innovation [32]. In addition, incentive measures from the aspects of
economy, public relations, and legal system should be taken
to encourage the development of biotechnology industry in a
socially responsible way. The industrial associations, societies, top research institutions, and leading companies should
formulate behavioral guidelines and standards and establish
ethical norms to maintain public confidence in the development of China’s biotechnology.
(5) Strengthening the publicity and education of the ethics
of science and technology to promote public participation in
building a new ecology of benign ethical governance of science and technology. China should establish an effective
dialogue mechanism among stakeholders, and strengthen the
education of popular biological science and ethics of science
and technology, especially for the fields that have local special ethical concerns and targeted sub-fields, so as to improve
the understanding of the public on the ethical issues in the
research of biotechnology [33]. On one hand, it is necessary to
establish appropriate mechanisms to monitor and identify
social ethical concerns, and encourage the public participation in extensive discussions and exchanges [34]. On the other
hand, it is suggested to pay attention to the popularization of
biotechnology for the public by innovating communication
methods and ensuring the accuracy of the communication
content, and improving the public’s rational understanding of
the complexity and uncertainty of this field, so as to gain the
understanding and support of the public.
(6) Promoting global collaboration on the governance of
ethical issues of biotechnology in terms of the top-level design and contributing Chinese wisdom. Ethical issues of
biotechnology are transnational and cross-cultural, and they
are common problems faced by all mankind. The ethical
governance of biotechnology in China must take into account
international concerns, in which parallel efforts and international consultation and cooperation are crucial. China should
maintain an active dialogue with the international community
(states and international organizations) and play a role in the
global governance of biotechnological ethics. In some advantageous fields, we should vigorously promote the construction of a dialogue mechanism and an international
institutional framework for ethical governance, and strive for
China’s discourse and initiative in global ethical governance
of biotechnology. China should seize the opportunities of
current development and reform of biotechnology, continue
to promote international cooperation in biotechnology research, deeply participate in global governance on biotechnological ethics, so as to accumulate experience and lay a
solid strategic foundation for the development and ethical
governance of biotechnology.
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Conclusion

The new wave reform of biotechnology governance focuses on ethics and safety, which involves not only technology development, international competition, and national
interests, but also differences in cultural values and conflict
of rules. The ethical issues of biotechnology have gradually
expanded from traditional disputes to frontier disputes with
the technological iterations. In addition, the integration of
biotechnology with information technology, artificial intelligence, big data, and other technologies have posed new
ethical challenges which have shaken the existing ethical
governance rules and systems for biotechnology, driving the
adjustment of science and technology governance in various
countries and promoting the arrival of the era of biotechnology development and ethical governance reform. As the
cornerstone of the national biotechnology strategy, the development and promotion of biotechnology should be conducted in a manner consistent with Chinese values and ethical
conduct. Adhering to the principle of sustainable governance
and considering the current advancement of science and
technology, China should promote the high-quality development of biotechnology on the one hand, and on the other
hand, adopt a multi-pronged approach to achieve comprehensive, flexible, and sustainable governance of ethical issues by conducting forward-looking ethical risk research and
judgment, improving regulatory system (with the supervision
department at the core), encouraging the participation of
multiple stakeholders (e.g., institutions, industries, and the
public), and taking part in global governance.
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